Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

Fintel reports that on February 12, 2025, HC Wainwright & Co. downgraded their outlook for Inhibikase Therapeutics ...

H.C. Wainwright downgraded Inhibikase Therapeutics (IKT) to Neutral from Buy without a price target after risvodetinib development was paused ...

Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is revealed that it is pausing development of risvodetinib following disappointing ...

Inhibikase Therapeutics announced results from a Phase 2 trial of its Parkinson’s disease drug, risvodetinib, a selective inhibitor of the non-receptor Abelson tyrosine kinases, in a filing to the US ...

Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and Inhibikase Therapeutics, Inc. (IKT) 10-day simple moving average is 2.65. Inhibikase Therapeutics, Inc. (IKT) stock price is 2.27 and ...

Alterity Therapeutics ATHE shares moved upwards by 95.9% to $5.7 during Thursday's pre-market session. The market value of their outstanding shares is at $49.8 million. T ...

Ger­man CD­MO Rentschler Bio­phar­ma is clos­ing down its cell and gene ther­a­py op­er­a­tions and shut­ter­ing a fa­cil­i­ty in the UK, which could af­fect up to … ...

In­hibikase Ther­a­peu­tics is slam­ming the brakes on its Parkin­son’s dis­ease pro­gram af­ter the can­di­date failed to im­prove symp­toms in a mid-stage test in treat­ment ...